Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
IMF Reaches Staff-Level Agreement With Egypt, Opening Path to $3.8 Billion in Funding 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
BOJ Minutes Reveal Growing Debate Over Interest Rate Hikes and Inflation Risks 
Italy Fines Apple €98.6 Million Over App Store Dominance 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
U.S. Stocks Rally to Record Highs as AI Rebound Fuels Holiday-Shortened Session 
Japan Revises Economic Growth Forecast as Stimulus Fuels Consumption and Investment 
Gold Price Breaks $4,500 as Safe-Haven Demand and Rate Cut Bets Fuel Rally 
US and Japan Fast-Track $550 Billion Strategic Investment Initiative 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
RBA Signals Possible Interest Rate Hike in 2026 as Inflation Pressures Persist 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Merck, a leading science and technology company that operates across life science, healthcare and electronics, has bought the chemical business of Mecaro Co. Ltd., a Korean company specializing in materials and components for semiconductors.
Merck acquired Mecaro in an effort to boost its line-up of materials used for the production of semiconductor products. The German firm further explained on Wednesday, Aug. 17, that the deal is part of the company’s electronics business unit’s “Level Up” growth program.
The agreement also includes investments of more than €3 billion or around $3.05 billion from 2021 to 2025 for innovation and capacities, where the focus will be four key priorities which are: scale, technology, portfolio, and capabilities.
At any rate, according to The Korea Times, the acquisition deal between Merck and Mecaro is worth €110 million. The pay scheme involves an upfront cash payment of €75 million and contingent milestone payments of up to €35 million.
The deal is expected to be completed and closed within the fourth quarter of this year. But then again, just like any other acquisition transaction, this is still subject to regulatory clearance and other customary closing conditions.
Under the agreement, Merck will be securing the production plant of Mecaro located in Eumseong, North Chungcheong Province, as well as its research and development (R&D) facility in Daejeon. It learned that Mecaro has about 100 dedicated staff and mainly produces precursors that are used in Thin Film deposition.
“In acquiring this portion of Mecaro’s business, we will continue to expand a key segment of our Semiconductor Solutions portfolio,” Merck’s chief executive officer of electronics and board member, Kai Beckmann, said in a press release.
He added, “Simultaneously, we are building on our localization efforts and gaining a state-of-the-art production facility in Eumseong and an R&D lab in Daejeon, both supporting our capacity expansion plans and these turnkey spaces will be one of the crucial elements in executing our Level Up investments in Korea.”
Mecaro’s president and CEO, Jae Jung Lee, further said it is looking forward to the partnership.
